Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
The first-in-class fully human IgG4 monoclonal antibody ulocuplumab that inhibits the binding of CXCR4 to CXCL12 appears to be safe in the treatment of patients with relapsed/refractory myeloma, yielding a high response rate when added to lenalidomide and dexamethasone with acceptable adverse events, according to the results of a phase Ib/II trial.
A suprachoroidally injected CLS-TA, an investigational formulation of triamcinolone acetonide, yields significant improvements in vision of patients with macular oedema, according to the results of the phase III PEACHTREE study.
Major depressive disorder (MDD) patients who do not respond at the second week of treatment with mirtazapine monotherapy, paroxetine monotherapy or their combination appear to show improvements at the eighth week of treatment, according to a study. The data do not support recommendations to routinely offer additional treatment or a switch in treatment strategy to patients who exhibit nonresponse early in the treatment.
Treatment with ustekinumab has been shown to be effective for ulcerative colitis (UC) in a real-world setting, according to a recent study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).
The standard 12-month duration of dual antiplatelet therapy (DAPT) remains the recommended regimen for patients receiving new-generation drug-eluting stents (DES) for the treatment of acute coronary syndrome (ACS) compared with a 3-month strategy despite the latter’s noninferiority to the former regimen, according to the results of the REDUCE* trial.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.